They need money to continue, and when they start the stem cell therapies then they will generate a lot of money, meantime they need money.

Stem Cells USA And Regenerative Medicine Congress, 20-21 September 2012, Boston
Main Category: Conferences
Article Date: 25 Jun 2012 - 7:00 PDT

The stem cell and regenerative medicine industry is facing a serious funding problem. Just as the first therapies are reaching commercialization, biotechs in phase 2 and 3 are struggling to raise the funds needed to finish their studies.

Over 300 biotechs, pharmas, investors, and suppliers will be meeting in Boston on September 20-21 at the Stem Cells USA and Regenerative Medicine Congress 2012.